Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buntanetap in Early Parkinson's Disease
NCT05357989Phase 3Completed
- Sponsor
- Annovis Bio, Inc.
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of buntanetap in Parkinson's disease (PD) (3 arms), sponsored by Annovis Bio, Inc. Primary endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part II at 6 months. Started Aug 2022; status: completed.
02
Drugs
buntanetap
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05357989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357989.